Executive summary of the American Radium Society Appropriate Use Criteria for the use of esophageal stents in patients with esophageal cancer: Systematic review and guidelines Guidelines
| Authors: | Russo, S.; Anker, C. J.; Codipilly, D. C.; Abood, G.; Akselrod, D.; Hallemeier, C. L.; Jethwa, K. R.; Jin, Z.; Kim, E.; Kennedy, T.; Lee, P.; Miller, E. D.; Newman, N. B.; Selfridge, J. E.; Sharma, N.; Small, W. Jr; Tchelebi, L.; Williams, V. M.; Simone, C. B. 2nd |
| Title: | Executive summary of the American Radium Society Appropriate Use Criteria for the use of esophageal stents in patients with esophageal cancer: Systematic review and guidelines |
| Abstract: | Objectives: Esophageal cancer (EC) often presents with dysphagia due to tumor obstruction. Esophageal stenting has the potential of palliating dysphagia, improving nutrition, preventing aspiration, and improving quality of life (QoL) but may be associated with risks. The present systematic review and guidelines are intended to assist treatment decision-making when considering stent placement in patients with EC based on the available evidence. Methods: Using the population, intervention, comparator, outcome, timing and study design framework, the evidence was assessed using Cochrane and PRISMA 2020 methodology. Eligible studies included prospective phase II-III trials and retrospective analyses published between January 1, 2010 and December 3, 2024 in the Ovid Medline database. These references were assessed by American Radium Society (ARS) Appropriate Use Criteria (AUC) methodology. RAND-UCLA consensus methodology was used to rate the appropriateness of the use of stents. Results: ARS AUC recommendations include (1) esophageal stenting is usually not appropriate in patients with early-stage EC in whom upfront surgery is planned; (2) esophageal stenting is usually not appropriate in patients with locally-advanced EC in whom neoadjuvant/perioperative therapy and esophagectomy or definitive chemoradiation is planned; (3) esophageal stenting may be appropriate in the setting of metastatic EC, especially in patients with short life expectancy with limited treatment options; (4) esophageal stenting is usually not appropriate for benign stricture following curative-intent therapy; (5) esophageal stenting is usually not appropriate for locally recurrent tumor in the setting of prior radiation; and (6) esophageal stenting is usually appropriate for management of tracheoesophageal fistula before curative-intent treatment. Conclusions: This ARS AUC summary provides guidelines for the use of esophageal stents in patients with EC provides based on available evidence. Copyright © 2025 The Author(s). Published by Wolters Kluwer Health, Inc. |
| Keywords: | dysphagia; esophageal cancer; tracheoesophageal fistula; esophageal stent; malignant tumor obstruction |
| Journal Title: | American Journal of Clinical Oncology |
| ISSN: | 0277-3732 |
| Publisher: | Lippincott Williams & Wilkins |
| Publication status: | Online ahead of print |
| Date Published: | 2025-06-25 |
| Online Publication Date: | 2025-06-25 |
| Language: | English |
| DOI: | 10.1097/coc.0000000000001222 |
| PUBMED: | 40557604 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Review -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work